- $24.05m
- $23.72m
- $1.35m
Annual balance sheet for IGC Pharma, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 12.3 | 14.6 | 10.5 | 3.35 | 1.2 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.133 | 1.92 | 0.597 | 0.131 | 0.091 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 17.8 | 23.5 | 15.1 | 6.47 | 3.71 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 10.4 | 11.3 | 9.87 | 8.54 | 3.89 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 29 | 35.9 | 26.8 | 17.2 | 9.9 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.95 | 2.37 | 2.44 | 1.9 | 2.34 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 2.45 | 3.06 | 2.94 | 2.27 | 2.58 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 26.5 | 32.8 | 23.9 | 14.9 | 7.32 |
Total Liabilities & Shareholders' Equity | 29 | 35.9 | 26.8 | 17.2 | 9.9 |
Total Common Shares Outstanding |